The treatment of dysmenorrhea with naproxen sodium: A report on two independent double-blind trials

https://doi.org/10.1016/0002-9378(77)90111-9Get rights and content

Abstract

The efficacy of naproxen sodium (naproxen-Na) in dysmenorrhea has been established in two independent double-blind (placebo-controlled) studies. An initial dose of 550 mg. of naproxen-Na was followed by 275 mg. every six hours for a maximum of five days. Twenty patients were included in Study I (10 treated with naproxen-Na) and 23 patients in Study II (12 treated with naproxen-Na). Each patient received the medication during four dysmenorrheic episodes. Thus, a total of 172 treatment courses could be evaluated. A variety of efficacy criteria were measured: frequency of pill intake, changes in pain intensity, the degree of relief achieved by the medication, and need for additional analgesics. In both studies naproxen-Na was demonstrated to be superior to the placebo treatment with high statistical significance in each of these parameters.

References (17)

There are more references available in the full text version of this article.

Cited by (76)

  • Nonsteroidal antiinflammatory drugs and reproduction

    1993, American Journal of Obstetrics and Gynecology
View all citing articles on Scopus

Naproxen-sodium is the sodium salt of a-2-(6′-methoxy-2′ naphthyl)-propionic acid.

View full text